Matthew Roden - 08 Jan 2026 Form 3 Insider Report for Aktis Oncology, Inc. (AKTS)

Reporting relationship: President and CEO, Director
Issuer ticker: AKTS
Reported as of: 08 Jan 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 08 Jan 2026, 21:05:21 UTC
Prior SEC filing: 10 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Matthew Roden

Key filing fact

Matthew Roden filed Form 3 for Aktis Oncology, Inc. (AKTS) on 08 Jan 2026.

Key facts

This page summarizes Matthew Roden's Form 3 filing for Aktis Oncology, Inc. (AKTS).
0 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 08 Jan 2026, 21:05.

Change

Previous filing in this sequence was filed on 10 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001828130 Primary reporting owner

RODEN MATTHEW

Relationship: President and CEO, Director
Address: C/O AKTIS ONCOLOGY, INC., 17 DRYDOCK AVENUE, SUITE 17-401, BOSTON
Signature: /s/ Matthew Roden
Signature date: 08 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKTS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 91,998
Date: 08 Jan 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKTS holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 08 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 578,277
Exercise price: $1.91
Footnotes: F1

AKTS holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 08 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 558,095
Exercise price: $3.66
Footnotes: F2

AKTS holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 08 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 618,757
Exercise price: $9.33
Footnotes: F3

AKTS holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 08 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 394,280
Exercise price: $18.00
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These options have vested in full.

Footnote F2

25% of the original number of shares subject to the option vested on November 1, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

Footnote F3

25% of the original number of shares subject to the option vested on October 9, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

Footnote F4

25% of the original number of shares subject to the option shall vest on January 8, 2027, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .